News & Events about Prothena Corporation Plc.
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it priced an underwritten public offering of 3,250,000 of its ordinary shares at a price to the...
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today presented data from the completed phase 3 VITAL study demonstrating that in a post hoc analysis of patients with...
Business Wire
2 months ago
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will present survival data from the phase 3 VITAL study at an oral presentation at the...
Prothena Co. plc (NASDAQ:PRTA Get Rating) CEO Gene G. Kinney sold 16,412 shares of the stock in a transaction that occurred on Wednesday, September 28th. The shares were sold at an average price of $53.38, for a total transaction of $876,072.56. Following the completion of the transaction, the chief...
Thinking about buying stock in Acumen Pharmaceuticals, Prothena Corp, Anavex Life Sciences, Ocugen, or OraSure Technologies? Thinking about buying stock in Acumen Pharmaceuticals, Prothena Corp, Anavex Life Sciences, Ocugen, or OraSure Technologies? PR Newswire NEW YORK, Sept. 28, 2022 NEW YORK...